SCHEMBL5147736

SCHEMBL5147736

CCOC(=O)[C@H](CO)NC(=O)OC(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
HTT P42858 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 3/20 0.50
MAPT P10636 3/20 0.50
CTSK P43235 6/20 0.48
CTSS P25774 4/20 0.48
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
ALOX12 P18054 1/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
SCN9A Q15858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8211606 1.00 CYP1A2 (0.62) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL12942567 0.88 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL12071191 0.88 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL12070120 0.88 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL12069015 0.88 CYP1A2 (0.64) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL11173165 0.87 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL2531297 0.87 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL1846647 0.87 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL7308713 0.87 CYP1A2 (0.59) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2
SCHEMBL31758034 0.86 CYP1A2 (0.56) CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120004764-A Preparation method of amino acid tert-butyl ether 四川什邡市三高生化实业有限公司 2025-05-16 CN claimed
US-20250270184-A1 PROCESSES FOR THE PREPARATION OF FINERENONE ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2025-08-28 US disclosed
CN-120004764-A Preparation method of amino acid tert-butyl ether 四川什邡市三高生化实业有限公司 2025-05-16 CN disclosed
CN-119775170-A Preparation method of sabatier starter intermediate 浙江工业大学 2025-04-08 CN disclosed
EP-4511365-A1 PROCESSES FOR THE PREPARATION OF FINERENONE Teva Pharmaceuticals International GmbH (CH) 2025-02-26 EP disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
WO-2023205164-A1 PROCESSES FOR THE PREPARATION OF FINERENONE TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2023-10-26 WO disclosed
US-20230190943-A1 ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2023-06-22 US disclosed
US-20230168196-A1 METHOD FOR DETECTING TYROSINE RESIDUE IN SAMPLE, AND TERBIUM COMPOUND TO BE USED FOR SUCH DETECTION NEC CORPORATION (JP) 2023-06-01 US disclosed
EP-1106606-A2 N-(3-piperidinylcarbonyl)-beta-alanine derivatives as paf antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-06-13 EP disclosed
US-6211175-B1 P-AMINOMETHYLBENZOIC ACID DERIVATIVES; CARDIOVASCULAR DISORDERS; NONHYPOTENSIVE KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 2001-04-03 US disclosed
EP-0807628-B1 Aromatic compound and pharmaceutical composition KUREHA CHEMICAL IND CO LTD (JP) 2000-12-20 EP disclosed
US-5932575-A Cardiac diseases improving agents KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 1999-08-03 US disclosed
US-5863913-A ALLEVIATION OF RENAL DYSFUNCTION WITHOUT AFFECTING BLOOD PRESSURE AT A LOW BLOOD CONCENTRATION. KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 1999-01-26 US disclosed
EP-0864568-A1 Agents for treatment of cardiac diseases KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) 1998-09-16 EP disclosed
EP-0807628-A1 Aromatic compound and pharmaceutical composition Kureha Chemical Industry Co., Ltd. (JP) 1997-11-19 EP disclosed
EP-0669912-A1 N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-09-06 EP disclosed
WO-1995008536-A1 N-(3-PIPERIDINYLCARBONYL)-BETA-ALANINE DERIVATIVES AS PAF ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-03-30 WO disclosed
EP-0292923-A2 Piperidine compounds and pharmaceutical uses thereof Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1988-11-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270184-A1 PROCESSES FOR THE PREPARATION OF FINERENONE CYP11B1, CYP11B2, HSD17B7 CYP1A2 88/4885CYP2C9 397/4885CYP2C19 159/4885
US-20230190943-A1 ALGINIC ACID DERIVATIVE BONDED TO NONSTEROIDAL ANTI-INFLAMMATORY COMPOUND ALG1, ALG8, ALG3 CYP1A2 4495/4885CYP2C9 3313/4885CYP2C19 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.